Loading…
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with pneumonitis. A multicenter, retrospective cohort stud...
Saved in:
| Published in: | Scientific reports 2023-03, Vol.13 (1), p.3698-3698, Article 3698 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c540t-5c2438c0635a7ae11d28635e7d38368a3c0727d4460b75c758a42e07cc035b9d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c540t-5c2438c0635a7ae11d28635e7d38368a3c0727d4460b75c758a42e07cc035b9d3 |
| container_end_page | 3698 |
| container_issue | 1 |
| container_start_page | 3698 |
| container_title | Scientific reports |
| container_volume | 13 |
| creator | Fujimoto, Daichi Miura, Satoru Tomii, Keisuke Sumikawa, Hiromitsu Yoshimura, Kenichi Wakuda, Kazushige Oya, Yuko Yokoyama, Toshihide Kijima, Takashi Asao, Tetsuhiko Tamiya, Motohiro Nakamura, Atsushi Yoshioka, Hiroshige Tokito, Takaaki Murakami, Shuji Tamiya, Akihiro Yokouchi, Hiroshi Watanabe, Satoshi Yamaguchi, Ou Morinaga, Ryotaro Jodai, Takayuki Ito, Kentaro Shiraishi, Yoshimasa Kogure, Yoshihito Shibaki, Ryota Yamamoto, Nobuyuki |
| description | Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with pneumonitis. A multicenter, retrospective cohort study of patients with non-squamous non-small cell lung cancer who received a combination of platinum, pemetrexed, and pembrolizumab was conducted. Patients with confirmed pneumonitis established by an independent multidisciplinary team were enrolled. For 53 patients with pneumonitis, radiographic features at diagnosis predominantly comprised an organizing pneumonia pattern (62%, 33/53). Twelve (23%) patients experienced a worsening respiratory status during pneumonitis management, which was associated with a high mortality rate (58%, 7/12) during treatment. Severe grade at pneumonitis diagnosis (
p
|
| doi_str_mv | 10.1038/s41598-023-30676-y |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d7954e13f28249d198db8ce843bb07a9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d7954e13f28249d198db8ce843bb07a9</doaj_id><sourcerecordid>2783541226</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-5c2438c0635a7ae11d28635e7d38368a3c0727d4460b75c758a42e07cc035b9d3</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQjRCIVqV_gAOKxIVLwJ-xfUFCFbSVKsEBzpZjz2a9SuzUTqiWX493U0rLAR_ssefNm_HTq6rXGL3HiMoPmWGuZIMIbShqRdvsn1WnBDHeEErI80fxSXWe8w6VxYliWL2sTmgrhVS0Pa36bwGWMQY_-1ybnKP1ZgZX3_l5W08wdikO_tcymq6ehiXXdgtjnLeQzLSvNzHVIYYm3y5mjCV7vIxmGGoLZRuW0NfWBAvpVfViY4YM5_fnWfXjy-fvF1fNzdfL64tPN43lDM0Nt4RRaVFLuREGMHZElhiEo7IMbahFggjHWIs6wa3g0jACSFiLKO-Uo2fV9crrotnpKfnRpL2OxuvjQ0y9Nmn2dgDthOIMMN0QSZhyWEnXSQuS0a5DwqjC9XHlmpZuBGchzMkMT0ifZoLf6j7-1EpJqSQpBO_uCVK8XSDPevT5oIwJUOTSRJRmkiEmCvTtP9BdXFIoUh1QlDNMSFtQZEXZFHNOsHkYBiN9sIVebaGLLfTRFnpfit48_sZDyR8TFABdAbmkQg_pb-__0P4GdkHErw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2783541226</pqid></control><display><type>article</type><title>Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer</title><source>PubMed Central（OA）</source><source>Publicly Available Content Database</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Fujimoto, Daichi ; Miura, Satoru ; Tomii, Keisuke ; Sumikawa, Hiromitsu ; Yoshimura, Kenichi ; Wakuda, Kazushige ; Oya, Yuko ; Yokoyama, Toshihide ; Kijima, Takashi ; Asao, Tetsuhiko ; Tamiya, Motohiro ; Nakamura, Atsushi ; Yoshioka, Hiroshige ; Tokito, Takaaki ; Murakami, Shuji ; Tamiya, Akihiro ; Yokouchi, Hiroshi ; Watanabe, Satoshi ; Yamaguchi, Ou ; Morinaga, Ryotaro ; Jodai, Takayuki ; Ito, Kentaro ; Shiraishi, Yoshimasa ; Kogure, Yoshihito ; Shibaki, Ryota ; Yamamoto, Nobuyuki</creator><creatorcontrib>Fujimoto, Daichi ; Miura, Satoru ; Tomii, Keisuke ; Sumikawa, Hiromitsu ; Yoshimura, Kenichi ; Wakuda, Kazushige ; Oya, Yuko ; Yokoyama, Toshihide ; Kijima, Takashi ; Asao, Tetsuhiko ; Tamiya, Motohiro ; Nakamura, Atsushi ; Yoshioka, Hiroshige ; Tokito, Takaaki ; Murakami, Shuji ; Tamiya, Akihiro ; Yokouchi, Hiroshi ; Watanabe, Satoshi ; Yamaguchi, Ou ; Morinaga, Ryotaro ; Jodai, Takayuki ; Ito, Kentaro ; Shiraishi, Yoshimasa ; Kogure, Yoshihito ; Shibaki, Ryota ; Yamamoto, Nobuyuki</creatorcontrib><description>Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with pneumonitis. A multicenter, retrospective cohort study of patients with non-squamous non-small cell lung cancer who received a combination of platinum, pemetrexed, and pembrolizumab was conducted. Patients with confirmed pneumonitis established by an independent multidisciplinary team were enrolled. For 53 patients with pneumonitis, radiographic features at diagnosis predominantly comprised an organizing pneumonia pattern (62%, 33/53). Twelve (23%) patients experienced a worsening respiratory status during pneumonitis management, which was associated with a high mortality rate (58%, 7/12) during treatment. Severe grade at pneumonitis diagnosis (
p
< 0.001), diffuse alveolar damage (DAD) pattern (
p
= 0.002), and disease extent ≥ 25% in the lungs (
p
= 0.009) were significantly associated with worsening respiratory status. Furthermore, post-diagnosis survival was significantly worse in severe pneumonitis (
p
= 0.02) than in mild and in patients with the DAD pattern than in those without (
p
< 0.0001). We showed detailed clinical course of patients with pneumonitis and reported several important influencing factors. Given the small number of trials on pneumonitis, our findings provide valuable information to guide the development of appropriate management guidelines and improve pneumonitis treatment.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-023-30676-y</identifier><identifier>PMID: 36878936</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/1612/1350 ; 692/499 ; 692/699/1785 ; Alveoli ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Chemotherapy ; Clinical trials ; Diagnosis ; Disease Progression ; Humanities and Social Sciences ; Humans ; Immunotherapy ; Lung cancer ; Lung Neoplasms - drug therapy ; Medical prognosis ; multidisciplinary ; Non-small cell lung carcinoma ; Patients ; Pembrolizumab ; Pneumonia ; Pneumonitis ; Respiration ; Retrospective Studies ; Science ; Science (multidisciplinary) ; Small cell lung carcinoma</subject><ispartof>Scientific reports, 2023-03, Vol.13 (1), p.3698-3698, Article 3698</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-5c2438c0635a7ae11d28635e7d38368a3c0727d4460b75c758a42e07cc035b9d3</citedby><cites>FETCH-LOGICAL-c540t-5c2438c0635a7ae11d28635e7d38368a3c0727d4460b75c758a42e07cc035b9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2783541226/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2783541226?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36878936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fujimoto, Daichi</creatorcontrib><creatorcontrib>Miura, Satoru</creatorcontrib><creatorcontrib>Tomii, Keisuke</creatorcontrib><creatorcontrib>Sumikawa, Hiromitsu</creatorcontrib><creatorcontrib>Yoshimura, Kenichi</creatorcontrib><creatorcontrib>Wakuda, Kazushige</creatorcontrib><creatorcontrib>Oya, Yuko</creatorcontrib><creatorcontrib>Yokoyama, Toshihide</creatorcontrib><creatorcontrib>Kijima, Takashi</creatorcontrib><creatorcontrib>Asao, Tetsuhiko</creatorcontrib><creatorcontrib>Tamiya, Motohiro</creatorcontrib><creatorcontrib>Nakamura, Atsushi</creatorcontrib><creatorcontrib>Yoshioka, Hiroshige</creatorcontrib><creatorcontrib>Tokito, Takaaki</creatorcontrib><creatorcontrib>Murakami, Shuji</creatorcontrib><creatorcontrib>Tamiya, Akihiro</creatorcontrib><creatorcontrib>Yokouchi, Hiroshi</creatorcontrib><creatorcontrib>Watanabe, Satoshi</creatorcontrib><creatorcontrib>Yamaguchi, Ou</creatorcontrib><creatorcontrib>Morinaga, Ryotaro</creatorcontrib><creatorcontrib>Jodai, Takayuki</creatorcontrib><creatorcontrib>Ito, Kentaro</creatorcontrib><creatorcontrib>Shiraishi, Yoshimasa</creatorcontrib><creatorcontrib>Kogure, Yoshihito</creatorcontrib><creatorcontrib>Shibaki, Ryota</creatorcontrib><creatorcontrib>Yamamoto, Nobuyuki</creatorcontrib><title>Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with pneumonitis. A multicenter, retrospective cohort study of patients with non-squamous non-small cell lung cancer who received a combination of platinum, pemetrexed, and pembrolizumab was conducted. Patients with confirmed pneumonitis established by an independent multidisciplinary team were enrolled. For 53 patients with pneumonitis, radiographic features at diagnosis predominantly comprised an organizing pneumonia pattern (62%, 33/53). Twelve (23%) patients experienced a worsening respiratory status during pneumonitis management, which was associated with a high mortality rate (58%, 7/12) during treatment. Severe grade at pneumonitis diagnosis (
p
< 0.001), diffuse alveolar damage (DAD) pattern (
p
= 0.002), and disease extent ≥ 25% in the lungs (
p
= 0.009) were significantly associated with worsening respiratory status. Furthermore, post-diagnosis survival was significantly worse in severe pneumonitis (
p
= 0.02) than in mild and in patients with the DAD pattern than in those without (
p
< 0.0001). We showed detailed clinical course of patients with pneumonitis and reported several important influencing factors. Given the small number of trials on pneumonitis, our findings provide valuable information to guide the development of appropriate management guidelines and improve pneumonitis treatment.</description><subject>631/67/1612/1350</subject><subject>692/499</subject><subject>692/699/1785</subject><subject>Alveoli</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Diagnosis</subject><subject>Disease Progression</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Medical prognosis</subject><subject>multidisciplinary</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Pembrolizumab</subject><subject>Pneumonia</subject><subject>Pneumonitis</subject><subject>Respiration</subject><subject>Retrospective Studies</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Small cell lung carcinoma</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9Uk1v1DAQjRCIVqV_gAOKxIVLwJ-xfUFCFbSVKsEBzpZjz2a9SuzUTqiWX493U0rLAR_ssefNm_HTq6rXGL3HiMoPmWGuZIMIbShqRdvsn1WnBDHeEErI80fxSXWe8w6VxYliWL2sTmgrhVS0Pa36bwGWMQY_-1ybnKP1ZgZX3_l5W08wdikO_tcymq6ehiXXdgtjnLeQzLSvNzHVIYYm3y5mjCV7vIxmGGoLZRuW0NfWBAvpVfViY4YM5_fnWfXjy-fvF1fNzdfL64tPN43lDM0Nt4RRaVFLuREGMHZElhiEo7IMbahFggjHWIs6wa3g0jACSFiLKO-Uo2fV9crrotnpKfnRpL2OxuvjQ0y9Nmn2dgDthOIMMN0QSZhyWEnXSQuS0a5DwqjC9XHlmpZuBGchzMkMT0ifZoLf6j7-1EpJqSQpBO_uCVK8XSDPevT5oIwJUOTSRJRmkiEmCvTtP9BdXFIoUh1QlDNMSFtQZEXZFHNOsHkYBiN9sIVebaGLLfTRFnpfit48_sZDyR8TFABdAbmkQg_pb-__0P4GdkHErw</recordid><startdate>20230306</startdate><enddate>20230306</enddate><creator>Fujimoto, Daichi</creator><creator>Miura, Satoru</creator><creator>Tomii, Keisuke</creator><creator>Sumikawa, Hiromitsu</creator><creator>Yoshimura, Kenichi</creator><creator>Wakuda, Kazushige</creator><creator>Oya, Yuko</creator><creator>Yokoyama, Toshihide</creator><creator>Kijima, Takashi</creator><creator>Asao, Tetsuhiko</creator><creator>Tamiya, Motohiro</creator><creator>Nakamura, Atsushi</creator><creator>Yoshioka, Hiroshige</creator><creator>Tokito, Takaaki</creator><creator>Murakami, Shuji</creator><creator>Tamiya, Akihiro</creator><creator>Yokouchi, Hiroshi</creator><creator>Watanabe, Satoshi</creator><creator>Yamaguchi, Ou</creator><creator>Morinaga, Ryotaro</creator><creator>Jodai, Takayuki</creator><creator>Ito, Kentaro</creator><creator>Shiraishi, Yoshimasa</creator><creator>Kogure, Yoshihito</creator><creator>Shibaki, Ryota</creator><creator>Yamamoto, Nobuyuki</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230306</creationdate><title>Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer</title><author>Fujimoto, Daichi ; Miura, Satoru ; Tomii, Keisuke ; Sumikawa, Hiromitsu ; Yoshimura, Kenichi ; Wakuda, Kazushige ; Oya, Yuko ; Yokoyama, Toshihide ; Kijima, Takashi ; Asao, Tetsuhiko ; Tamiya, Motohiro ; Nakamura, Atsushi ; Yoshioka, Hiroshige ; Tokito, Takaaki ; Murakami, Shuji ; Tamiya, Akihiro ; Yokouchi, Hiroshi ; Watanabe, Satoshi ; Yamaguchi, Ou ; Morinaga, Ryotaro ; Jodai, Takayuki ; Ito, Kentaro ; Shiraishi, Yoshimasa ; Kogure, Yoshihito ; Shibaki, Ryota ; Yamamoto, Nobuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-5c2438c0635a7ae11d28635e7d38368a3c0727d4460b75c758a42e07cc035b9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>631/67/1612/1350</topic><topic>692/499</topic><topic>692/699/1785</topic><topic>Alveoli</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Diagnosis</topic><topic>Disease Progression</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Medical prognosis</topic><topic>multidisciplinary</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Pembrolizumab</topic><topic>Pneumonia</topic><topic>Pneumonitis</topic><topic>Respiration</topic><topic>Retrospective Studies</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Small cell lung carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujimoto, Daichi</creatorcontrib><creatorcontrib>Miura, Satoru</creatorcontrib><creatorcontrib>Tomii, Keisuke</creatorcontrib><creatorcontrib>Sumikawa, Hiromitsu</creatorcontrib><creatorcontrib>Yoshimura, Kenichi</creatorcontrib><creatorcontrib>Wakuda, Kazushige</creatorcontrib><creatorcontrib>Oya, Yuko</creatorcontrib><creatorcontrib>Yokoyama, Toshihide</creatorcontrib><creatorcontrib>Kijima, Takashi</creatorcontrib><creatorcontrib>Asao, Tetsuhiko</creatorcontrib><creatorcontrib>Tamiya, Motohiro</creatorcontrib><creatorcontrib>Nakamura, Atsushi</creatorcontrib><creatorcontrib>Yoshioka, Hiroshige</creatorcontrib><creatorcontrib>Tokito, Takaaki</creatorcontrib><creatorcontrib>Murakami, Shuji</creatorcontrib><creatorcontrib>Tamiya, Akihiro</creatorcontrib><creatorcontrib>Yokouchi, Hiroshi</creatorcontrib><creatorcontrib>Watanabe, Satoshi</creatorcontrib><creatorcontrib>Yamaguchi, Ou</creatorcontrib><creatorcontrib>Morinaga, Ryotaro</creatorcontrib><creatorcontrib>Jodai, Takayuki</creatorcontrib><creatorcontrib>Ito, Kentaro</creatorcontrib><creatorcontrib>Shiraishi, Yoshimasa</creatorcontrib><creatorcontrib>Kogure, Yoshihito</creatorcontrib><creatorcontrib>Shibaki, Ryota</creatorcontrib><creatorcontrib>Yamamoto, Nobuyuki</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Journals (ProQuest Database)</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujimoto, Daichi</au><au>Miura, Satoru</au><au>Tomii, Keisuke</au><au>Sumikawa, Hiromitsu</au><au>Yoshimura, Kenichi</au><au>Wakuda, Kazushige</au><au>Oya, Yuko</au><au>Yokoyama, Toshihide</au><au>Kijima, Takashi</au><au>Asao, Tetsuhiko</au><au>Tamiya, Motohiro</au><au>Nakamura, Atsushi</au><au>Yoshioka, Hiroshige</au><au>Tokito, Takaaki</au><au>Murakami, Shuji</au><au>Tamiya, Akihiro</au><au>Yokouchi, Hiroshi</au><au>Watanabe, Satoshi</au><au>Yamaguchi, Ou</au><au>Morinaga, Ryotaro</au><au>Jodai, Takayuki</au><au>Ito, Kentaro</au><au>Shiraishi, Yoshimasa</au><au>Kogure, Yoshihito</au><au>Shibaki, Ryota</au><au>Yamamoto, Nobuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2023-03-06</date><risdate>2023</risdate><volume>13</volume><issue>1</issue><spage>3698</spage><epage>3698</epage><pages>3698-3698</pages><artnum>3698</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with pneumonitis. A multicenter, retrospective cohort study of patients with non-squamous non-small cell lung cancer who received a combination of platinum, pemetrexed, and pembrolizumab was conducted. Patients with confirmed pneumonitis established by an independent multidisciplinary team were enrolled. For 53 patients with pneumonitis, radiographic features at diagnosis predominantly comprised an organizing pneumonia pattern (62%, 33/53). Twelve (23%) patients experienced a worsening respiratory status during pneumonitis management, which was associated with a high mortality rate (58%, 7/12) during treatment. Severe grade at pneumonitis diagnosis (
p
< 0.001), diffuse alveolar damage (DAD) pattern (
p
= 0.002), and disease extent ≥ 25% in the lungs (
p
= 0.009) were significantly associated with worsening respiratory status. Furthermore, post-diagnosis survival was significantly worse in severe pneumonitis (
p
= 0.02) than in mild and in patients with the DAD pattern than in those without (
p
< 0.0001). We showed detailed clinical course of patients with pneumonitis and reported several important influencing factors. Given the small number of trials on pneumonitis, our findings provide valuable information to guide the development of appropriate management guidelines and improve pneumonitis treatment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>36878936</pmid><doi>10.1038/s41598-023-30676-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2023-03, Vol.13 (1), p.3698-3698, Article 3698 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_d7954e13f28249d198db8ce843bb07a9 |
| source | PubMed Central（OA）; Publicly Available Content Database; Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access |
| subjects | 631/67/1612/1350 692/499 692/699/1785 Alveoli Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Clinical trials Diagnosis Disease Progression Humanities and Social Sciences Humans Immunotherapy Lung cancer Lung Neoplasms - drug therapy Medical prognosis multidisciplinary Non-small cell lung carcinoma Patients Pembrolizumab Pneumonia Pneumonitis Respiration Retrospective Studies Science Science (multidisciplinary) Small cell lung carcinoma |
| title | Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T10%3A02%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pneumonitis%20associated%20with%20pembrolizumab%20plus%20chemotherapy%20for%20non-squamous%20non-small%20cell%20lung%20cancer&rft.jtitle=Scientific%20reports&rft.au=Fujimoto,%20Daichi&rft.date=2023-03-06&rft.volume=13&rft.issue=1&rft.spage=3698&rft.epage=3698&rft.pages=3698-3698&rft.artnum=3698&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-023-30676-y&rft_dat=%3Cproquest_doaj_%3E2783541226%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c540t-5c2438c0635a7ae11d28635e7d38368a3c0727d4460b75c758a42e07cc035b9d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2783541226&rft_id=info:pmid/36878936&rfr_iscdi=true |